Brief: Cantargia Reports New Preclinical Data On Antitumor Effects Of Nadunolimab

Cantargia AB

06/03/2024 08:12

March 6 (Reuters) - Cantargia AB  CANTA.ST :
    * REPORTED ON TUESDAY NEW PRECLINICAL DATA ON ANTITUMOR
EFFECTS OF
NADUNOLIMAB IN PANCREATIC CANCER
    * CSO: NADUNOLIMAB'S ABILITY TO BLOCK THIS FIBROSIS IS VERY
PROMISING AND GIVES A STRONG SUPPORT TO THE CLINICAL AND
TRANSLATIONAL RESULTS WE HAVE TO DATE
    * DATA WILL BE PRESENTED AS A POSTER AT THE AMERICAN
ASSOCIATION
FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2024 IN SAN DIEGO

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nNDLb9B716
 Further company coverage:  CANTA.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))